Leerink Partnrs Brokers Raise Earnings Estimates for IDXX

Key Points

• Analysts at Leerink Partnrs have raised their Q4 2025 EPS estimate for IDEXX Laboratories to $2.92, up from $2.91, reflecting positive sentiment about the company's financial performance.
• IDEXX Laboratories reported a strong quarterly EPS of $3.63, surpassing expectations, with revenue increasing by 10.6% year-over-year to $1.11 billion.
• Multiple analysts have upgraded their target prices for IDEXX shares, with the new average target now at $656.50, indicating a consensus rating of "Moderate Buy."

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - Equities research analysts at Leerink Partnrs raised their Q4 2025 earnings per share (EPS) estimates for shares of IDEXX Laboratories in a note issued to investors on Monday, October 13th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $2.92 for the quarter, up from their previous forecast of $2.91. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the company posted $2.44 EPS. The business's quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS.

A number of other equities research analysts have also recently issued reports on the stock. BTIG Research boosted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. upped their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. Weiss Ratings reiterated a "buy (b-)" rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $656.50.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $633.32 on Tuesday. IDEXX Laboratories has a twelve month low of $356.14 and a twelve month high of $688.12. The stock's 50 day moving average price is $640.50 and its 200-day moving average price is $545.08. The company has a market capitalization of $50.67 billion, a PE ratio of 52.73, a PEG ratio of 3.99 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the sale, the executive vice president directly owned 6,156 shares of the company's stock, valued at $4,011,249.60. This trade represents a 46.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 over the last ninety days. 0.98% of the stock is owned by corporate insiders.

Institutional Trading of IDEXX Laboratories

Several hedge funds have recently bought and sold shares of IDXX. GAMMA Investing LLC lifted its stake in IDEXX Laboratories by 42.7% in the 1st quarter. GAMMA Investing LLC now owns 2,187 shares of the company's stock worth $918,000 after purchasing an additional 654 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in IDEXX Laboratories by 13.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock valued at $10,731,000 after purchasing an additional 2,931 shares during the last quarter. 1900 Wealth Management LLC grew its holdings in IDEXX Laboratories by 9.7% during the 1st quarter. 1900 Wealth Management LLC now owns 850 shares of the company's stock valued at $357,000 after purchasing an additional 75 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in IDEXX Laboratories by 9.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 43,786 shares of the company's stock valued at $18,388,000 after purchasing an additional 3,728 shares during the last quarter. Finally, Western Pacific Wealth Management LP grew its holdings in IDEXX Laboratories by 50.0% during the 1st quarter. Western Pacific Wealth Management LP now owns 303 shares of the company's stock valued at $127,000 after purchasing an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.